Radiation Therapy Rivals Surgery for Early-Stage Liver Cancer in Largest Study Yet
A multinational study of 4,913 patients finds EBRT delivers survival outcomes comparable to surgery and ablation for early hepatocellular carcinoma.
Summary
A large international study pooling data from nearly 5,000 liver cancer patients found that external beam radiation therapy (EBRT) produces survival outcomes comparable to surgery and other standard treatments for early-stage hepatocellular carcinoma (HCC). Patients with very early-stage disease who had never been treated before had a median survival that was not yet reached after a median follow-up of five years. Even those with early-stage disease survived a median of 5.4 years. Higher radiation doses and more recent treatment years were linked to better survival. These findings strongly support adding EBRT as a recommended first-line option in clinical guidelines for liver cancer decision-making.
Detailed Summary
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer death worldwide. Despite decades of use, external beam radiation therapy (EBRT) has only recently gained traction as a guideline-endorsed treatment, largely because high-quality survival data were lacking. This landmark study provides the most comprehensive individual patient data analysis to date, making a compelling case for EBRT's role alongside surgery and ablation.
Researchers conducted a systematic review of published studies on EBRT for HCC and invited corresponding authors to contribute raw patient-level data. The final cohort included 4,913 patients from institutions across North America, Europe, Asia, and Australia, with a median follow-up of five years. Outcomes were analyzed using Kaplan-Meier survival methods and multivariable Cox regression, stratified by Barcelona Clinic Liver Cancer (BCLC) stage and prior treatment history.
For very early-stage (BCLC-0) treatment-naive patients, median overall survival was not reached, with the lower bound of the confidence interval exceeding 8.6 years. Early-stage (BCLC-A) treatment-naive patients achieved a median overall survival of 5.4 years. Across all BCLC-0 and BCLC-A patients regardless of prior treatment, median OS was 6.8 and 4.6 years respectively. Ablative radiation doses and more recent treatment years were independently associated with reduced mortality risk, suggesting ongoing technical improvements are enhancing outcomes.
Multivariable analysis confirmed that worse liver function (Child-Pugh B or C), higher tumor burden, poorer performance status, and more advanced disease stage all predicted higher mortality — consistent with known HCC prognostic factors.
These survival figures are competitive with outcomes reported for hepatic resection, thermal ablation, and transplantation in comparable patient populations. The findings directly support updating BCLC clinical decision algorithms to formally include EBRT as a first-line treatment option. Clinicians managing HCC patients who are poor surgical candidates should consider EBRT a viable curative-intent alternative.
Key Findings
- Treatment-naive BCLC-0 liver cancer patients had median survival not yet reached after 5-year follow-up with EBRT.
- Early-stage (BCLC-A) treatment-naive patients achieved a median overall survival of 5.4 years with EBRT.
- Ablative radiation doses were independently associated with significantly reduced risk of death.
- EBRT survival outcomes appear comparable to surgical resection and thermal ablation in early-stage HCC.
- More recent treatment year was associated with better survival, suggesting continued technical improvement.
Methodology
This was a systematic review and individual patient data meta-analysis including 4,913 HCC patients from multinational institutions. Survival analyses used Kaplan-Meier methods with results stratified by BCLC stage and treatment-naïve status; multivariable random-effects Cox proportional hazards models identified prognostic factors. Median follow-up was 5.0 years.
Study Limitations
Summary is based on the abstract only, as the full text is not open access. As a retrospective pooled analysis, selection bias across contributing institutions cannot be excluded. Patient populations, radiation techniques, and dose regimens varied across international centers, potentially limiting uniformity of results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.